GlassScriptPhysician profile
Abha Choudhary
NPI 1912106170
$35,154.35
in general payments reported to CMS, 2019-2025
16 companies · $23K in 2025
The $23K reported for 2025 was more than what 94% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2021: $74.12 · 2022: $32.13 · 2023: $214 · 2024: $12K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $31K · Food and Beverage: $2,011 · Travel and Lodging: $1,790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $31,113.00 |
| Food and Beverage | $2,010.81 |
| Travel and Lodging | $1,789.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $28,924.30 | 2024-2025 | |
| Genzyme Corporation | $5,206.88 | 2025 | |
| Abbott Laboratories | $201.97 | 2021-2025 | Cardiomems, Freestyle Libre 3 |
| Beta Bionics, INC. | $163.15 | 2023-2024 | Ilet Bionic Pancreas |
| Companion Medical, INC. | $119.77 | 2019 | |
| Tolmar, INC. | $81.66 | 2023-2025 | Fensolvi |
| Tandem Diabetes Care, INC. | $71.82 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $65.70 | 2019-2025 | Omnipod |
| Neurocrine Biosciences, INC. | $57.40 | 2025 | |
| Xeris Pharmaceuticals, INC. | $57.32 | 2021-2023 | Gvoke Hypopen |
| Dexcom, INC. | $56.15 | 2021-2023 | Dexcom G6 Transmitter |
| Abbvie INC. | $51.05 | 2024 | |
| Medtronic, INC. | $35.23 | 2023 | Inpen Smart Insulin Delivery System |
| Eton Pharmaceuticals, INC. | $24.02 | 2025 | Increlex, Khindivi, Alkindi |
| Sequel Med Tech, LLC | $23.22 | 2025 | Twiist |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zealand Pharma US, INC. | $14.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abha Choudhary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.